|Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care|
Eunice S. Wang, MD
|Release Date: August 29, 2018|
Expiration Date: August 29, 2019
Managing patients with high-risk MDS is complex and requires an approach to therapy that is based on risk stratification to maximize outcomes and minimize toxicity. In this activity, Dr. Wang summarizes strategies for optimizing patient selection and treatment using current standards of care and available data from clinical trials. She also identifies strategies for the appropriate use of hypomethylating agents and discusses clinical trial data that will help guide future directions in managing high-risk MDS patients.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Onconova Therapeutics Inc., and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|